Pneumologie 2004; 58(7): 483-488
DOI: 10.1055/s-2004-818466
© Georg Thieme Verlag Stuttgart · New York

Einfluss unterschiedlicher Dosen von Budesonid auf die exhalierte NO-Konzentration und die EPX-Konzentration im Urin bei Kindern mit Asthma bronchiale

Effect of Two Doses of Budesonide on Exhaled Nitric Oxide and Urinary EPX Excretion in Asthmatic ChildrenK.  Storm van's Gravesande1 , J.  Mattes1 , A.  Endlicher1 , K.  Alving2 , G.  Ihorst1 , J.  Kühr1
  • 1Zentrum für Kinderheilkunde und Jugendmedizin, Universitätsklinikum Freiburg
  • 2Karolinska Institute, Department of Physiology and Pharmacology, Stockholm, Schweden
Wir danken der Firma AstraZeneca, Wedel, für die Unterstützung dieses Projektes.
Further Information

Publication History

Eingang: 19. Dezember 2003

Nach Revision akzeptiert: 30. März 2004

Publication Date:
16 July 2004 (online)


Das Ausmaß der bronchialen Inflammation beim Asthma bronchiale kann mit Hilfe von nichtinvasiven Methoden untersucht werden und ermöglicht das Therapieansprechen zu evaluieren. In dieser doppelblinden und randomisierten Studie wurde der Einfluss von 200 µg und 800 µg Budesonid/Tag auf die Konzentration von exhaliertem Stickstoffmonoxid (eNO), auf die Exkretion des eosinophilen Protein X (EPX) und auf Lungenfunktionsparameter bei 24 steroidnaiven Kindern und Jugendlichen mit leichtem bis mittelschwerem Asthma bronchiale über einen Zeitraum von 8 Wochen untersucht. Nach 8 Wochen nahm in beiden Gruppen die eNO-Konzentration gegenüber dem Ausgangswert signifikant ab [Median (90 % Intervall): 200 µg: - 17,2 ppb (- 54,6 bis 0,9); 800 µg: - 13,2 ppb (- 44,6 bis - 1,7); p < 0,025]. In der Hochdosisgruppe nahm die EPX-Exkretion ebenfalls gegenüber dem Ausgangswert signifikant nach 8 Wochen ab, was jedoch nicht in der Niedrigdosisgruppe der Fall war [200 µg: - 10,3 µg/mmol Kreatinin (- 116,2 bis 50,5), p = 0,9; 800 µg: - 49,2 µg/mmol Kreatinin (- 231,0 bis 48,7), p = 0,02]. Die Abnahme der eNO-Konzentration und der EPX-Exkretion nach 8 Wochen ergab zwischen beiden Therapiegruppen keinen signifikanten Unterschied (eNO: p = 0,66; EPX: p = 0,04). Zusammenfassend kann eine Tagesdosis von 800 µg Budesonid über einen Zeitraum von acht Wochen verglichen mit einer Tagesdosis von 200 µg Budesonid weder die eNO-Konzentration noch die EPX-Exkretion bei Kindern mit mildem bis mittelschwerem Asthma bronchiale stärker beeinflussen.


The use of objective outcome measures that assess airway inflammation in pediatric asthma can provide a good evaluation of asthma severity and treatment response. In this double-blind and randomized study the effects of 200 µg of budesonide and 800 µg of budesonide on markers of inflammation (exhaled nitric oxide (eNO), eosinophil protein X (EPX) excretion in urine) and on lung function (FEV1) were prospectively investigated in 24 ICS-naive children with mild persistent to moderate persistent asthma over a period of eight weeks. After eight weeks of treatment 200 µg and 800 µg of budesonide led to a significant decrease (p < 0.025) in eNO [median (90 % interval): 200 µg: - 17.2 ppb (- 54.6 to 0.9); 800 µg: - 13.2 ppb (- 44.6 to - 1.7)]. A significant change in urinary EPX excretion was only observed in the high dose group [200 µg: - 10.3 µg/mmol creatinine (- 116.2 to 50.5), p = 0.9; 800 µg: - 49.2 µg/mmol creatinine (- 231.0 to 48.7), p = 0.02]. However, a significant difference between the change from baseline after 8 weeks of either group was found neither for eNO (p = 0.66) nor for EPX excretion (p = 0.04). In conclusion, our data demonstrate that 800 µg budesonide per day did not show any advantage in reduction of airway inflammation, measured by eNO and urinary EPX excretion, in children with mild persistent to moderate persistent asthma.


  • 1 Global Initiatives for Asthma (GINA) .(Revised 1998). Pocket guide for asthma management and prevention. Bethesda, Md: US Department of Health and Human Services, National Institutes of Health, National Heart Lung, and Blood Institute, NIH Publication No. 96 - 3659B November 1998
  • 2 Haahtela T. Early treatment of asthma.  Allergy. 1999;  54 74-81
  • 3 Lim S, Jatakanon A, John M. et al . Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma.  Am J Respir Crit Care Med. 1999;  159 22-30
  • 4 Kristjansson S, Strannegard I L, Strannegard O. et al . Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment.  J Allergy Clin Immunol. 1996;  97 1179-1187
  • 5 Lugosi E, Halmerbauer G, Frischer T. et al . Urinary eosinophil protein X in relation to disease activity in childhood asthma.  Allergy. 1997;  52 584-588
  • 6 Massaro A F, Mehta S, Lilly C M. et al . Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects.  Am J Respir Crit Care Med. 1996;  153 1510-1514
  • 7 Kharitonov S A, Yates D H, Barnes P J. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients.  Am J Respir Crit Care Med. 1996;  153 454-457
  • 8 Jatakanon A, Lim S, Kharitonov S A. et al . Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma.  Thorax. 1998;  53 91-95
  • 9 Jones S L, Kittelson J, Cowan J O. et al . The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control.  Am J Respir Crit Care Med. 2001;  164 738-743
  • 10 Baraldi E, Carra S, Dario C. et al . Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children.  Am J Respir Crit Care Med. 1999;  159 262-266
  • 11 Labbe A, Aublet-Cuvelier B, Jouaville L. et al . Prospective longitudinal study of urinary eosinophil protein X in children with asthma and chronic cough.  Pediatr Pulmonol. 2001;  31 354-362
  • 12 Pedersen S, Hansen O R. Budesonide treatment of moderate and severe asthma in children: a dose-response study.  J Allergy Clin Immunol. 1995;  95 29-33
  • 13 Tukiainen H, Taivainen A, Majander R. et al . Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma.  Respir Med. 2000;  94 678-683
  • 14 Wilson A M, Lipworth B J. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma.  Am J Med. 2000;  108 269-275
  • 15 Molen T van der, Kerstjens H A. Starting inhaled corticosteroids in asthma: when, how high, and how long.  Eur Respir J. 2000;  15 3-4
  • 16 Standardization of spirometry-1987 update. Statement of the American Thoracic Society.  Am Rev Respir Dis. 1987;  136 285-298
  • 17 Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.  Am J Respir Crit Care Med. 1999;  160 2104-2117
  • 18 Mattes J, Storm van's Gravesande K, Reining U. et al . NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma.  Eur Respir J. 1999;  13 1391-1395
  • 19 Storm van's Gravesande K, Mattes J, Gruntjens T. et al . Circadian variation of urinary eosinophil protein X in asthmatic and healthy children.  Clin Exp Allergy. 1999;  29 1497-1501
  • 20 Lonnkvist K, Hellman C, Lundahl J. et al . Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal.  J Allergy Clin Immunol. 2001;  107 812-817
  • 21 Archer H, Creese K, Doull I. Higher dose inhaled steroids in childhood asthma. Conventional doses do have side effects (Letter).  Bmj. 2001;  322 1546
  • 22 Cates C. Higher dose inhaled steroids in childhood asthma. Why isn't titration advocated more often in delivery of inhaled drugs?.  (Letter) Bmj. 2001;  322 1546
  • 23 Jonasson G, Carlsen K H, Jonasson C. et al . Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma.  Allergy. 2000;  55 740-748
  • 24 Vathenen A S, Knox A J, Wisniewski A. et al . Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma.  Am Rev Respir Dis. 1991;  143 1317-1321
  • 25 Molen T van der, Meyboom-de Jong B, Mulder H H. et al . Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment.  Am J Respir Crit Care Med. 1998;  158 121-125
  • 26 Lundberg J O, Nordvall S L, Weitzberg E. et al . Exhaled nitric oxide in paediatric asthma and cystic fibrosis.  Arch Dis Child. 1996;  75 323-326
  • 27 Artlich A, Hagenah J U, Jonas S. et al . Exhaled nitric oxide in childhood asthma.  Eur J Pediatr. 1996;  155 698-701
  • 28 Alving K, Weitzberg E, Lundberg J M. Increased amount of nitric oxide in exhaled air of asthmatics.  Eur Respir J. 1993;  6 1368-1370
  • 29 Gaston B, Drazen J M, Loscalzo J. et al . The biology of nitrogen oxides in the airways.  Am J Respir Crit Care Med. 1994;  149 538-551
  • 30 Kharitonov S A, Yates D, Robbins R A. et al . Increased nitric oxide in exhaled air of asthmatic patients.  Lancet. 1994;  343 133-135
  • 31 Kharitonov S A, Yates D, Springall D R. et al . Exhaled nitric oxide is increased in asthma.  Chest. 1995;  107 156S-157S
  • 32 Silkoff P E, Wakita S, Chatkin J. et al . Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma.  Am J Respir Crit Care Med. 1999;  159 940-944
  • 33 Baraldi E, Azzolin N M, Cracco A. et al . Reference values of exhaled nitric oxide for healthy children 6 - 15 years old.  Pediatr Pulmonol. 1999;  27 54-58
  • 34 Kharitonov S A, O'Connor B J, Evans D J. et al . Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide.  Am J Respir Crit Care Med. 1995;  151 1894-1899
  • 35 Kharitonov S A, Yates D H, Chung K F. et al . Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients.  Eur Respir J. 1996;  9 196-201
  • 36 Piacentini G L, Bodini A, Costella S. et al . Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children.  Eur Respir J. 1999;  13 1386-1390
  • 37 Jatakanon A, Lim S, Chung K F. et al . An inhaled steroid improves markers of airway inflammation in patients with mild asthma.  Eur Respir J. 1998;  12 1084-1088
  • 38 Barnes P J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms.  Clin Sci (Colch). 1998;  94 557-572
  • 39 Jatakanon A, Kharitonov S, Lim S. et al . Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma.  Thorax. 1999;  54 108-114
  • 40 Pedersen B, Dahl R, Karlstrom R. et al . Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking.  Am J Respir Crit Care Med. 1996;  153 1519-1529
  • 41 Allen H D, Thong I G, Clifton-Bligh P. et al . Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma.  Pediatr Pulmonol. 2000;  29 188-193

Karin Storm van's Gravesande

Zentrum für Kinderheilkunde und Jugendmedizin

Mathildenstraße 1

79106 Freiburg